PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-59.37%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-86.14%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-763.74%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-763.74%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-12450.00%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-10160.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-10160.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.27%
Positive OCF growth while AR is negative. John Neff would see this as a clear operational advantage vs. the competitor.
67.00%
Positive FCF growth while AR is negative. John Neff would see a strong competitive edge in net cash generation.
-48.13%
Negative 10Y revenue/share CAGR while AR stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-85.70%
Negative 5Y CAGR while AR stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-80.18%
Negative 3Y CAGR while AR stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
73.40%
OCF/share CAGR of 73.40% while AR is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-68.02%
Negative 5Y OCF/share CAGR while AR is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-67.08%
Negative 3Y OCF/share CAGR while AR stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-716.99%
Negative 10Y net income/share CAGR while AR is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-212.50%
Negative 5Y net income/share CAGR while AR is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-732.46%
Negative 3Y CAGR while AR is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
0.18%
Equity/share CAGR of 0.18% while AR is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-59.22%
Negative 5Y equity/share growth while AR is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-71.24%
Negative 3Y equity/share growth while AR is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
397.82%
Dividend/share CAGR of 397.82% while AR is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
7.00%
Dividend/share CAGR of 7.00% while AR is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-50.19%
Negative near-term dividend growth while AR invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
0.50%
AR growth of 0.50% while AR is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
-13.56%
Negative asset growth while AR invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-19.31%
We have a declining book value while AR shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.20%
We’re deleveraging while AR stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-6.86%
We cut SG&A while AR invests at 14.17%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.